Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
9.64
+0.05 (0.57%)
At close: Jul 24, 2025, 4:00 PM
9.65
+0.02 (0.16%)
After-hours: Jul 24, 2025, 4:10 PM EDT

Company Description

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.

It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels.

The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Evolus, Inc.
Evolus logo
CountryUnited States
Founded2012
IPO DateFeb 8, 2018
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees332
CEODavid Moatazedi

Contact Details

Address:
520 Newport Center Drive, Suite 1200
Newport Beach, California 92660
United States
Phone949 284 4555
Websiteevolus.com

Stock Details

Ticker SymbolEOLS
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001570562
CUSIP Number30052C107
ISIN NumberUS30052C1071
Employer ID46-1385614
SIC Code2834

Key Executives

NamePosition
David MoatazediPresident, Chief Executive Officer and Director
Tomoko Yamagishi-DresslerChief Marketing Officer
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D.Chief Medical Officer and Head of Research and Development
Nareg SagherianHead of Global Investor Relations and Corporate Communications
Jeffrey J. PlumerGeneral Counsel
Kurt KnabSenior Vice President of Sales
Jessica NovakSenior Vice President of Human Resources

Latest SEC Filings

DateTypeTitle
Jun 16, 2025144Filing
Jun 13, 2025144Filing
Jun 6, 20258-KCurrent Report
May 27, 20258-KCurrent Report
May 15, 2025SCHEDULE 13GFiling
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 7, 202510-QQuarterly Report
May 7, 20258-KCurrent Report
May 5, 20258-KCurrent Report